Complete response to imatinib treatment in jejunal leiomyosarcoma subsequently developing gastrointestinal stromal tumor and desmoid tumor

Yuji Kurihara, Yoshio Sakai, Takeshi Tomita


A unique case of a 50-year-old Japanese male with jejunal leiomyosarcoma (LMS) who subsequently developed gastrointestinal stromal tumor (GIST) and desmoid tumor (DT) during five years and six months after the initial surgery is reported. The patient was treated with surgery and oral imatinib mesylate and achieved a complete response. He is still under oral imatinib mesylate therapy. To the best of our knowledge, this is the first case of a LMSsubsequently developing GIST and DT in the intestine. As imatinib mesylate targets both c-KIT and PDGFR and since LMS, GIST and DT share the expression of c-KIT and/or PDGFR, our patient has benefited from the continual treatment with imatinib mesylate. Furthermore, tyrosine kinase inhibitors may be a possible future treatment option for LMS associated with GIST and DT.


Jejunal leiomyosarcoma, GIST, desmoid tumor

Full Text:



Insabato L, Masone S, Campione S, Vigliar E, Staibano S, Tornillo L. Coexistence of primary gastric giant cell-rich leiomyosarcoma and gastrointestinal stromal tumor. Int J Surg Pathol 20:74-78, 2012.

Arts R, Bosscha K, Ranschaert E, Vogelaar J. Small bowel leiomyosarcoma: A case report and literature review. Turk J Gastroenterol 23:381-384, 2012.

Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J. Gas- trointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: A clinicopathologic,

immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 27:625-641, 2003.

Katz SC, DeMatteo RP. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 97: 350-359, 2008.

Khan M, Bozas G, Cooke J, Wedgwood K, Maraveyas A. Mesenteric desmoid tumor developing on the site of an excised gastrointestinal stromal tumor. Rare Tumors 2: e33, 2010.

Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol 23:1335-1340, 2012.

Pan SY, Morrison H. Epidemiology of cancer of small intestine. World J Gastrointest Oncol 3: 33-42, 2011.

Akwari OE, Dozois RR, Weiland LH, Beahrs OH. Leiomyosarcoma of the small and large bowel. Cancer 42:1375-1384, 1978.

Evans HL. Smooth muscle tumors of the gastrointestinal tract: a study of 56 cases followed for a minimum of 10 years. Cancer 56:2242-2250, 1985.

Gill SS, Heuman DM, Mihas AA. Small intestinal neoplasms. J Clin Gastroenterol 33: 267-282, 2001.

Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O'Meara AT, Amezcua CA. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 90:402-406, 2003

Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, Ueland FR, van Nagell JR, Ahmed MM, Lele SM. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 91:9-14, 2003.

Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura

Y, Shinomura Y, Kitamura Y. Gain-of-function mutations

of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.

Demetri GD, von Mehren M, Blanke CD, Van den

Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620-625, 2008.

Gonçalves R, Linhares E, Albagli R, Valadão M, Vilhena B, Romano S, Ferreira CG. Occurrence of other tumors in patients with GIST. Surg Oncol 10: e140–e143, 2010.

Clark SK, Phillips RK. Desmoidsin familial adeno-matous polyposis. Br J Surg 83: 1494-1504, 1996.

Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173: 1518-1527, 2008

Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 23: 117-126, 2008.

Colombo C, Foo WC, Whiting D, Young ED, Lusby K, Pollock RE, Lazar AJ, Lev D. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol 27:641-649, 2012.

Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24: 1195-1203, 2006.

Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17: 4082-4090, 2011.


  • There are currently no refbacks.